Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6263692 | 1.00 | ALDH1A1 (0.61) | ALDH1A1ALOX5CYP2D6MEN1KMT2A | |
| SCHEMBL20720467 | 0.96 | ALDH1A1 (0.57) | ALDH1A1ALOX5CYP2D6MEN1KMT2A | |
| SCHEMBL2991559 | 0.96 | ALDH1A1 (0.67) | ALDH1A1ALOX5CYP2D6MEN1KMT2A | |
| SCHEMBL6688258 | 0.96 | ALDH1A1 (0.67) | ALDH1A1ALOX5CYP2D6MEN1KMT2A | |
| SCHEMBL15612484 | 0.96 | ALDH1A1 (0.54) | ALDH1A1ALOX5 | |
| SCHEMBL3262787 | 0.92 | ALDH1A1 (0.61) | ALDH1A1ALOX5CYP2D6MEN1KMT2A | |
| SCHEMBL6380069 | 0.92 | ALDH1A1 (0.61) | ALDH1A1ALOX5CYP2D6MEN1KMT2A | |
| SCHEMBL3262784 | 0.92 | ALDH1A1 (0.61) | ALDH1A1ALOX5CYP2D6MEN1KMT2A | |
| SCHEMBL9579128 | 0.92 | ALDH1A1 (0.61) | ALDH1A1ALOX5CYP2D6MEN1KMT2A | |
| SCHEMBL9140661 | 0.92 | ALDH1A1 (0.61) | ALDH1A1ALOX5CYP2D6MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021154976-A1 | METHODS OF TREATING BRAIN CANCER WITH PANOBINOSTAT | SECURA BIO, INC. (US) | 2021-08-05 | — | — | WO | disclosed |
| EP-2139850-B1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC (CA) | 2018-09-12 | — | — | EP | disclosed |
| US-9636298-B2 | Prodrugs of compounds that enhance antifungal activity and compositions of said prodrugs | METHYLGENE INC (CA) | 2017-05-02 | — | — | US | disclosed |
| US-20170000749-A1 | Methods for Treating Cognitive Disorders Using Inhibitors of Histone Deacetylase | FMR LLC | 2017-01-05 | — | — | US | disclosed |
| US-20160222026-A1 | Dibenzo[B,F][1,4]oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors | FMR LLC | 2016-08-04 | — | — | US | disclosed |
| CN-103561747-B | Method for targeted treatment of frontotemporal lobar degeneration | FORUM PHARMACEUTICALS, INC. (US) | 2016-04-06 | — | — | CN | disclosed |
| EP-2966078-A2 | Inhibitors of histone deacetylase | MethylGene Inc. (CA) | 2016-01-13 | — | — | EP | disclosed |
| US-9193749-B2 | Dibenzo[b,f][1,4]oxazepin-11-yl-N-hydroxybenzamides as HDAC inhibitors | FORUM PHARMACEUTICALS, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-9096565-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2015-08-04 | — | — | US | disclosed |
| US-20150080325-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE | ENVIVO PHARMACEUTICALS, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| US-20060270730-A1 | Histone deacetylase inhibitors as immunosuppressants | KATOPODIS ANDREAS | 2006-11-30 | — | — | US | disclosed |
| US-20060264415-A1 | Inhibitors of histone deacetylase | METHYLGENE INC. | 2006-11-23 | — | — | US | disclosed |
| WO-2006102760-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2006-10-05 | — | — | WO | disclosed |
| US-7067551-B2 | Deacetylase inhibitors | NOVARTIS AG (CH) | 2006-06-27 | — | — | US | disclosed |
| US-20050085507-A1 | p-phenylethenyl hydroxamates; anticarcinogenic, antitumor, antiproliferative agents; regulating p21 promoter; improved stability | SECURA BIO, INC. | 2005-04-21 | — | — | US | disclosed |
| US-20050032899-A1 | Cyclooxygenase-2 inhibitor/histone deacetylase inhibitor combination | NOVARTIS AG (CH) | 2005-02-10 | — | — | US | disclosed |
| US-6833384-B2 | E. g., N-Hydroxy-3-(4-(((2-(1H-indol-3-yl)-ethyl)amino)-amino)methyl)-phenyl)-2E-2 -propenamide; histone deacetylase inhibitors; antiproliferative agents; antitumor agents; anticarcinogenic agents | NOVARTIS AG (CH) | 2004-12-21 | — | — | US | disclosed |
| US-20040024067-A1 | Deacetylase inhibitors | ATHYRIUM OPPORTUNITIES III ACQUISITION LP | 2004-02-05 | — | — | US | disclosed |
| US-6552065-B2 | Antiproliferative agents | NOVARTIS AG (CH) | 2003-04-22 | — | — | US | disclosed |
| US-20030018062-A1 | Deacetylase inhibitors | SECURA BIO, INC. | 2003-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264415-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC3, HDAC11 | ALDH1A1 781/4885ALOX5 4550/4885CYP2D6 3759/4885 |
| US-20050085507-A1 | p-phenylethenyl hydroxamates; anticarcinogenic, antitumor, antiproliferative agents; regulating p21 promoter; improved stability | TP53, CDKN1A, HDAC1 | ALDH1A1 835/4885ALOX5 4195/4885CYP2D6 3932/4885 |
| US-20060270730-A1 | Histone deacetylase inhibitors as immunosuppressants | HDAC1, HDAC2, HDAC5 | ALDH1A1 1127/4885ALOX5 1889/4885CYP2D6 3914/4885 |
| US-20150080325-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC5, HDAC2 | ALDH1A1 1127/4885ALOX5 3140/4885CYP2D6 3723/4885 |
| US-20040024067-A1 | Deacetylase inhibitors | HDAC1, HDAC3, HDAC6 | ALDH1A1 812/4885ALOX5 4047/4885CYP2D6 4401/4885 |
| US-20170000749-A1 | Methods for Treating Cognitive Disorders Using Inhibitors of Histone Deacetylase | HDAC5, KAT2A, HDAC1 | ALDH1A1 1086/4885ALOX5 2997/4885CYP2D6 4032/4885 |
| US-20050032899-A1 | Cyclooxygenase-2 inhibitor/histone deacetylase inhibitor combination | HDAC2, HDAC9, HDAC1 | ALDH1A1 643/4885ALOX5 310/4885CYP2D6 2692/4885 |
| US-20160222026-A1 | Dibenzo[B,F][1,4]oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors | HDAC1, HDAC2, HDAC4 | ALDH1A1 235/4885ALOX5 2652/4885CYP2D6 1008/4885 |
| US-20030018062-A1 | Deacetylase inhibitors | HDAC1, HDAC3, HDAC6 | ALDH1A1 812/4885ALOX5 4047/4885CYP2D6 4401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.